BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38328071)

  • 1. Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma.
    Tumuluru S; Godfrey JK; Cooper A; Yu J; Chen X; MacNabb BW; Venkataraman G; Zha Y; Pelzer B; Song J; Duns G; Sworder BJ; Bolen C; Penuel E; Postovalova E; Kotlov N; Bagaev A; Fowler N; Smith SM; Alizadeh AA; Steidl C; Kline J
    bioRxiv; 2024 Apr; ():. PubMed ID: 38328071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
    Kinoshita H; Bollard CM; Toner K
    Semin Hematol; 2023 Nov; 60(5):329-337. PubMed ID: 38336529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Nuvvula S; Dahiya S; Patel SA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
    Wang J; Shen K; Mu W; Li W; Zhang M; Zhang W; Li Z; Ge T; Zhu Z; Zhang S; Chen C; Xing S; Zhu L; Chen L; Wang N; Huang L; Li D; Xiao M; Zhou J
    Front Immunol; 2022; 13():873789. PubMed ID: 35572515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
    Zhu H; Deng H; Mu J; Lyu C; Jiang Y; Deng Q
    Onco Targets Ther; 2021; 14():4023-4037. PubMed ID: 34239307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
    Nagler A; Perriello VM; Falini L; Falini B
    Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
    Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
    Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-based therapies in diffuse large B-cell lymphoma.
    McCurry D; Flowers CR; Bermack C
    Expert Opin Investig Drugs; 2023; 32(6):479-493. PubMed ID: 37394970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma.
    Bao F; Wan W; He T; Qi F; Liu G; Hu K; Lu XA; Yang P; Dong F; Wang J; Jing H
    Cancer Gene Ther; 2019 Jul; 26(7-8):248-255. PubMed ID: 30622321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
    Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
    Jalbert JJ; Wu N; Chen CI; Ambati S; Ge W; Arnason JE
    Adv Ther; 2022 Jun; 39(6):2630-2640. PubMed ID: 35397110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era.
    Atallah-Yunes SA; Robertson MJ; Davé UP; Ghione P; Perna F
    Front Immunol; 2022; 13():901365. PubMed ID: 35720352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies.
    Sawalha Y
    J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
    Tu S; Zhou X; Guo Z; Huang R; Yue C; He Y; Li M; Chen Y; Liu Y; Chang LJ; Li Y
    Front Oncol; 2019; 9():1350. PubMed ID: 31867275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.